SXTC (China SXT Pharmaceuticals) EBIT: $-8.37 Mil (TTM As of Sep. 2025)

What is China SXT Pharmaceuticals EBIT?

China SXT Pharmaceuticals SXTC -7.48% 26 EBIT is $-8.37 Mil as of Sep. 2025. GuruFocus rates SXTC with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

China SXT Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was $-6.34 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was $-8.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China SXT Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2025 was -591.74%. China SXT Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -3,858.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 88.26%.

China SXT Pharmaceuticals (NAS:SXTC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China SXT Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

	ROC % (Q: Sep. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2025 )	+	Invested Capital (Q: Sep. 2025 ))	/ count )
=	-12.678 * ( 1 - 0% )	/	( (1.927	+	2.358)	/ 2 )
=	-12.678	/	2.1425
=	-591.74 %

where

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	21.664	-	4.453	-	( 18.099	-	max(0, 6.012	-	21.296	+	18.099	))
=	1.927

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	26.353	-	3.914	-	( 21.166	-	max(0, 5.961	-	26.042	+	21.166	))
=	2.358

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

China SXT Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2025		Q: Sep. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-12.674	/	( ( (0.355 + max(-2.642, 0))	+	(0.302 + max(-1.569, 0)) )	/	2 )
=	-12.674	/	( ( 0.355	+	0.302 )	/	2 )
=	-12.674	/	0.3285
=	-3,858.14 %

where Working Capital is:

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.301	+	0.828	+	0.469)	-	(4.453	+	0.059	+	0.728)
=	-2.642

	Working Capital		(Q: Sep. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.336	+	0.751	+	1.26)	-	(3.914	+	0.065	+	0.937)
=	-1.569

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China SXT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2025 )
	=	-8.372	/	-9.486
	=	88.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals EBIT Related Terms

China SXT Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's EBIT can be seen below:

China SXT Pharmaceuticals EBIT Chart

China SXT Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

EBIT

Get a 7-Day Free Trial

-2.20

-5.37

-5.46

-2.55

-2.66

China SXT Pharmaceuticals Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25
EBIT	Get a 7-Day Free Trial													-9.36	6.81	-0.62	-2.04	-6.34

SXTC vs YCBD, CVSI, INM: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China SXT Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's EV-to-EBIT falls into.

Save Embed

26GF Score

China SXT Pharmaceuticals Inc SXTC

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

China SXT Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.37 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-8.37 Mil mean?

China SXT Pharmaceuticals (SXTC) has a EBIT of $-8.37 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China SXT Pharmaceuticals.

Is China SXT Pharmaceuticals' EBIT too high?

China SXT Pharmaceuticals' current EBIT is $-8.37 Mil. Overall, China SXT Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.

How does China SXT Pharmaceuticals' EBIT compare to YCBD and CVSI?

China SXT Pharmaceuticals' EBIT of $-8.37 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China SXT Pharmaceuticals. China SXT Pharmaceuticals's current EBIT is $-8.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is China SXT Pharmaceuticals stock overvalued right now?

China SXT Pharmaceuticals (SXTC) has a current EBIT of $-8.37 Mil. The current EBIT is $-8.37 Mil. China SXT Pharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current EBIT is $-8.37 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China SXT Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies YCBD CVSI INM GELS LVRLF BUDZ CABR CTTH SBFM SNOA XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300

Website http://www.sxtchina.com

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

26GF Score

Get the complete analysis for SXTC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.35

Price

View SXTC Analysis

See EBIT data for all stocks →